Boustead IPO Client Soliton Announces Submission for IRB Approval of Pivotal Cellulite Trial Protoco
Boustead Securities, LLC, IPO client Soliton, Inc., (Nasdaq: SOLY) ("Soliton" or the "Company"), a medical device company with a new and proprietary platform technology licensed from The University of Texas on behalf of the MD Anderson Cancer Center ("MD Anderson"), announced that the company has submitted its pivotal cellulite clinical trial protocol for independent Institutional Review Board ("IRB") approval.
Dr. Chris Capelli, President, CEO and co-founder of Soliton explained, "We have submitted our protocol for the pivotal cellulite study to Advara for review and approval. Based on the results we recently announced from our proof of concept cellulite trial, we expect this larger pivotal trial to form the basis for FDA clearance of our Rapid Acoustic Pulse (RAP) device. We hope to receive approval from the IRB in the very near future which will enable us to move forward with the site initiation visits and ultimate treatment of patients in this important study." These clinical trials are still in early stages and there is no guarantee that any specific outcome will be achieved.
Boustead Securities served as Sole Underwriter for Soliton’s $10,862,955 Reg A+ Initial Public Offering on Nasdaq on February 19, 2019, and was the Co-Placement Agent for SOLY’s $9,450,000 sale of securities to certain institutional and accredited investors on June 19, 2019.
About Soliton, Inc.
Soliton, Inc. is a pre-revenue stage medical device company with a proprietary platform technology licensed from MD Anderson. The Company’s first commercial product uses rapid pulses of designed acoustic shockwaves to accelerate the removal of unwanted tattoos. The Company is based in Houston, Texas, and is actively engaged in bringing this device to the market. For more information about the Company, please visit: http://www.soliton.com.
About Boustead Securities, LLC
Boustead Securities, LLC (“Boustead”) is an investment banking firm that executes and advises on IPOs, mergers and acquisitions, capital raises and restructuring assignments in a wide array of industries, geographies and transactions, for a broad client base. Boustead’s core value proposition is the ability to create opportunity through innovative solutions and tenacious execution. With experienced professionals in the United States and around the world, Boustead’s team moves quickly and provides a broad spectrum of sophisticated financial advice and services. Boustead is a majority owned subsidiary of Boustead & Company Limited, a diversified non-bank financial institution. For more information, please visit www.boustead1828.com.
Contact: Dan McClory, Head of Equity Capital Markets Boustead Securities, LLC Managing Director E-mail: firstname.lastname@example.org Phone: (949) 502 - 4408
About Boustead & Company Limited
Boustead & Company Limited is a diversified and comprehensive non-bank financial institution with offices in Los Angeles, New York, San Francisco, London and Beijing that is rapidly expanding in growth markets throughout the US and Asia. Through its principals and fully-licensed subsidiaries Boustead & Company possesses rich experience and exceptional capabilities in capital markets deal execution and is dedicated to providing best-in-class one-stop financial services to clients. Boustead’s comprehensive financial services platform consists of four operating units: Boustead Securities, LLC a US-based FINRA Broker/Dealer and middle-market investment bank; Sutter Securities Group, Inc. which owns three FINRA-regulated entities: Sutter Securities Inc., Sutter Securities Clearing, LLC and FlashFunders Funding Portal, LLC, along with fund manager Sutter Capital Management, Inc.; Sutter Capital Partners, LLC a California Registered Investment Advisor; and Boustead Capital Markets, LLP a London-based FCA-regulated company.
About Sutter Securities Group, Inc.
Headquartered in Irvine, California, Sutter Securities Group, Inc. (“SSG”), founded in 2013, through its affiliates, is an innovator and investment banking solutions provider. SSG owns and operates Sutter Securities Clearing, LLC and Sutter Securities Inc., both FINRA member broker-dealers; Sutter Capital Partners, LLC, a California Registered Investment Advisor, Sutter Shareholder Services, LLC, a SEC-registered transfer agent; FlashFunders Funding Portal, LLC, a FINRA member funding portal; and Sutter Capital Management, Inc. Sutter Securities Group, through its affiliates, operates a U.S.-based online securities platform whose underlying technology and regulatory infrastructure are designed to enable issuers to engage in Regulation D, Regulation A (known as Reg A+), Regulation S, Regulation CF and fully registered S-1 and F-1 Initial Public Offerings in compliance with applicable federal, state and non-U.S. securities laws. SSG is a majority owned subsidiary of Boustead & Company Limited, a diversified non-bank financial institution. Additional information is available at www.SutterSecurities.com and www.flashfunders.com.
Some of the statements in this release are forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, Section 21E of the Securities Exchange Act of 1934 and the Private Securities Litigation Reform Act of 1995, which involve risks and uncertainties. Forward-looking statements in this press release include, without limitation, the ability of Soliton's acoustic shockwave device to reduce cellulite in a larger clinical trial or to receive FDA clearance for the cellulite indication, and the ability of Soliton to commence such larger clinical trial within the next few months. These statements relate to future events, future expectations, plans and prospects. Although Soliton believes that the expectations reflected in such forward-looking statements are reasonable as of the date made, expectations may prove to have been materially different from the results expressed or implied by such forward-looking statements. Soliton has attempted to identify forward-looking statements by terminology including ''believes,'' ''estimates,'' ''anticipates,'' ''expects,'' ''plans,'' ''projects,'' ''intends,'' ''potential,'' ''may,'' ''could,'' ''might,'' ''will,'' ''should,'' ''approximately'' or other words that convey uncertainty of future events or outcomes to identify these forward-looking statements. These statements are only predictions and involve known and unknown risks, uncertainties, and other factors, including those discussed under in our SEC filings, including under the heading "Item 1A. Risk Factors" in the Form 10-K for year ended December 31, 2018 we filed with the SEC and updated from time to time in our Form 10-Q filings and in our other public filings with the SEC. Any forward-looking statements contained in this release speak only as of its date. Soliton undertakes no obligation to update any forward-looking statements contained in this release to reflect events or circumstances occurring after its date or to reflect the occurrence of unanticipated events.